There are currently no strategies for restoration of PTEN activity in cancer; however, patients with cancers that have PTEN LOF mutations are selectively being treated in clinical trials with PI3K inhibitors (to PI3Kα or β) to limit the PI3K/AKT signaling pathway that has become unrestrained due to excess PI(3,4,5)P3 production following reduced PTEN activity [66]. Here, AKT1 is linked to cancer.